They didn't withdraw after all. Teva announced today the closing of its acquisition of privately-held CoGenesys Inc.
During its Investor Day, they announced the Company’s long term goals of doubling the size of its business by 2012, and generating revenues of $20 billion and net income margins exceeding 20%.
Now that Teva is approved for Neupogen and they have CoGenesys's tech, I bet they will go for PEG-filgrastim (Neulasta). The advantage of Neulasta over Neupogen is it only requires one administration per cycle of chemotherapy due to its increased half-life. Product sales in 2006 were $2,300 MM and growing at ~ 12%. US patent expiry approximately 2017.
Market Data 
Markets 
AI
